Updates and news related to prostate cancer:


Increased Risk with Use of Docetaxel

The risk for febrile neutropenia from second-line docetaxel (Taxotere) is high in patients with metastatic castration-resistant prostate cancer, particularly for men older than age 75 years and those with multiple comorbidities.

Contribute a Story

Do you have something to contribute? Send it to pchelp@pcsanm.org